News Release

Hormone therapy remains most effective treatment for menopause symptoms of hot flashes and night sweats

NAMS video on the 20th anniversary of The Women's Health Initiative helps dispel misconceptions regarding risks of hormones

Business Announcement

The Menopause Society

CLEVELAND, Ohio (June 1, 2022)—It has been 20 years since The Women’s Health Initiative suggested a link between hormone therapy (HT) and increased risks for breast cancer, heart disease, and stroke. Although much has been learned since 2002, many women still suffer needlessly with menopause symptoms from fear of using HT. A new video from The North American Menopause Society (NAMS) summarizes why HT remains the most effective, safest treatment for menopause symptoms.

The video, Hormone Therapy: Understanding the Risks and Benefits, is hosted by NAMS past-president Dr. Marla Shapiro and features expert insights from Dr. Juliana Kling, chair of Women’s Health, Internal Medicine at the Mayo Clinic in Scottsdale, Arizona.

“Twenty years later, women are still asking about the risks of HT,” says Dr. Kling. “Although they also remain concerned about heart disease and stroke, their top concern is breast cancer, even though more recent studies have demonstrated that the risks of hormones are low and are far outweighed by the benefits.”

According to Dr. Kling, there is overwhelming evidence that HT remains the most effective treatment for an array of menopause symptoms, especially hot flashes and night sweats, two of the most common and burdensome symptoms. Moreover, the associated risk is very low for most women without contraindications for hormones and is primarily associated with the timing of initiation of HT.

“For most women who are aged younger than 60 years or within 10 years of their last menstrual cycle when they initiate HT, the health risks are very low,” says Dr. Kling, who likened the level of risk to that of obesity or a sedentary lifestyle. “Duration of therapy influences that risk, but that doesn’t mean there is a definitive cutoff of 5 years or so for all women. In addition, any potential increased risk related to a longer duration of HT can often be offset by a healthy lifestyle that includes a balanced diet and exercise.”

The video details how the various formulations of HT affect a woman’s risk levels. Women with a uterus who need progesterone to protect against endometrial cancer, for example, may face a slightly increased risk of breast cancer, whereas women on estrogen alone have actually been found to have a lower risk of breast cancer and a lower mortality rate from breast cancer than women on placebo.

“Unfortunately, a lot of women going through the menopause transition are suffering unnecessarily because of misrepresentation of the data from 20 years ago,” says Dr. Stephanie Faubion, NAMS medical director. “It’s important that women be presented with the benefits and risks on the basis of accurate data and then make the decision that is best for their specific situation in collaboration with their healthcare professionals. For most healthy women, HT is the best option for management of disruptive menopause symptoms.”

The video is part of NAMS’ comprehensive video series for women and professionals on important midlife health topics. For more information about menopause and healthy aging, visit

Founded in 1989, The North American Menopause Society (NAMS) is North America’s leading nonprofit organization dedicated to promoting the health and quality of life of all women during midlife and beyond through an understanding of menopause and healthy aging. Its multidisciplinary membership of 2,000 leaders in the field—including clinical and basic science experts from medicine, nursing, sociology, psychology, nutrition, anthropology, epidemiology, pharmacy, and education—makes NAMS uniquely qualified to serve as the definitive resource for health professionals and the public for accurate, unbiased information about menopause and healthy aging. To learn more about NAMS, visit

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.